In This Article:
As February 2025 unfolds, global markets are grappling with geopolitical tensions and consumer spending concerns, leading to fluctuating indices and cautious investor sentiment. Amid these uncertainties, identifying growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 50.1% |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
| Pricol (NSEI:PRICOLLTD) | 25.4% | 25.2% |
| Pharma Mar (BME:PHM) | 11.9% | 45.4% |
| Elliptic Laboratories (OB:ELABS) | 26.8% | 121.1% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| HANA Micron (KOSDAQ:A067310) | 18.3% | 119.4% |
| Fulin Precision (SZSE:300432) | 13.6% | 71% |
| Findi (ASX:FND) | 35.8% | 133.7% |
Let's take a closer look at a couple of our picks from the screened companies.
Fabege
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fabege AB (publ) is a Swedish property company specializing in the development, investment, and management of commercial premises, with a market cap of SEK27.18 billion.
Operations: The company generates revenue primarily from Management at SEK3.07 billion, followed by Project at SEK28 million, Birger Bostad at SEK244 million, and Processing at SEK243 million.
Insider Ownership: 14.0%
Fabege's recent earnings report shows a turnaround with net income of SEK 455 million compared to a loss last year, and revenue slightly declining to SEK 864 million. The company has secured an eight-year lease with SBAB Bank, adding SEK 20.8 million in net letting effect. Insider activity indicates more buying than selling recently, though not substantial. Despite low forecasted revenue growth at 2.1% annually, Fabege is expected to become profitable over the next three years, outperforming the Swedish market growth rate.
-
Dive into the specifics of Fabege here with our thorough growth forecast report.
-
Our expertly prepared valuation report Fabege implies its share price may be too high.
Medicover
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medicover AB (publ) is a company that offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK31.08 billion.
Operations: The company's revenue is primarily derived from Healthcare Services, generating €1.46 billion, and Diagnostic Services, contributing €658 million.
Insider Ownership: 11.1%
Medicover's strategic focus on growth is evident with its 2025 earnings guidance projecting organic revenue above €2.2 billion, building on 2024 sales of €2.09 billion. Despite a slight dip in net income to €16.7 million, the company anticipates significant annual profit growth at 32.4%, outpacing the Swedish market's 9.6%. The leadership transition to John Stubbington as CEO from May 2025 aligns with Medicover's forward-looking strategy, although insider trading activity remains limited recently.